Cargando…

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively

SIMPLE SUMMARY: DNMT3A mutation has been associated with adverse outcomes. In this study, we aimed to investigate the impact of DNMT3A status on NPM1 MRD predictive value for survival in a retrospective cohort of acute myeloid leukemia (AML) patients aged over 60 years old treated intensively. A tot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heiblig, Maël, Duployez, Nicolas, Marceau, Alice, Lebon, Delphine, Goursaud, Laure, Plantier, Isabelle, Stalnikiewich, Laure, Cambier, Nathalie, Balsat, Marie, Fossard, Gaëlle, Labussière-Wallet, Hélène, Barraco, Fiorenza, Ducastelle-Lepretre, Sophie, Sujobert, Pierre, Huet, Sarah, Hayette, Sandrine, Ghesquières, Hervé, Thomas, Xavier, Preudhomme, Claude
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124973/ https://www.ncbi.nlm.nih.gov/pubmed/33947035 http://dx.doi.org/10.3390/cancers13092156

Ejemplares similares

Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
por: Daull, Anne-Marie, et al.
Publicado: (2022)

Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience
por: Heiblig, Maël, et al.
Publicado: (2019)

How to Transform an Exceptional Case Report Into a Therapy: Following the Frog Out of the Box
por: Heiblig, Maël, et al.
Publicado: (2021)

Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a ‘Real-Life’ Study
por: Laurino, Marica, et al.
Publicado: (2020)

Torque Teno Virus Viral Load as a Marker of Immune Function in Allogeneic Haematopoietic Stem Cell Transplantation Recipients
por: Mouton, William, et al.
Publicado: (2020)

Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience
por: Diarra, Ava, et al.
Publicado: (2022)

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
por: Lambert, Juliette, et al.
Publicado: (2014)

Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults
por: Fenwarth, Laurène, et al.
Publicado: (2021)

Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication
por: Antherieu, Gabriel, et al.
Publicado: (2021)

Clinical outcome of therapy‐related acute myeloid leukemia patients. Real‐life experience in a University Hospital and a Cancer Center in France
por: Belhabri, Amine, et al.
Publicado: (2023)

Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience
por: Heiblig, Maël, et al.
Publicado: (2016)

Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies
por: Hayette, Sandrine, et al.
Publicado: (2021)

Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database
por: Antherieu, Gabriel, et al.
Publicado: (2023)

PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML
por: Falini, Brunangelo, et al.
Publicado: (2023)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
por: Jentzsch, Madlen, et al.
Publicado: (2023)

Sickle cell disease and acute leukemia: one case report and an extensive review
por: Cannas, Giovanna, et al.
Publicado: (2023)

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
por: Duchmann, Matthieu, et al.
Publicado: (2022)

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study
por: Vasseur, Loïc, et al.
Publicado: (2023)

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
por: Kayser, S, et al.
Publicado: (2016)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
por: Berthon, Celine, et al.
Publicado: (2020)

Acute Promyelocytic Leukemia
por: Thomas, Xavier, et al.
Publicado: (2020)

Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
por: Boudry, Augustin, et al.
Publicado: (2022)

Publisher Correction: Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
por: Boudry, Augustin, et al.
Publicado: (2022)

A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia
por: Duployez, Nicolas, et al.
Publicado: (2018)

Quantitative Assessment of Vacuolization of Myeloid Precursors in VEXAS Syndrome
por: Rabut, Audrey, et al.
Publicado: (2023)

New Quantitative Method to Identify NPM1 Mutations in Acute Myeloid Leukaemia
por: Huet, Sarah, et al.
Publicado: (2013)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
por: Fathi, Amir, et al.
Publicado: (2023)

Panton-Valentine Leukocidin–Secreting Staphylococcus aureus Pneumonia Complicating COVID-19
por: Duployez, Claire, et al.
Publicado: (2020)

Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use
por: Lesieur, Auriane, et al.
Publicado: (2020)

Spontaneous remission in three cases of AML M5 with NPM1 mutation
por: Camus, Vincent, et al.
Publicado: (2015)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
por: McDuff, Fiona Kate Elizabeth, et al.
Publicado: (2011)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended
por: Huet, Sarah, et al.
Publicado: (2014)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)
por: Djamai, Hanane, et al.
Publicado: (2021)

Recurrent Mutations of the Active Adenylation Domain of UBA1 in Atypical Form of VEXAS Syndrome
por: Faurel, Alyx, et al.
Publicado: (2023)

Real‐life challenges using personalized prognostic scoring systems in acute myeloid leukemia
por: Calleja, Anne, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_383nvadls95qrr7o1i3lajsceq